Literature DB >> 9224744

Loss of heterozygosity of chromosome 14q in low- and high-grade meningiomas.

J Y Tse1, H K Ng, K M Lau, K W Lo, W S Poon, D P Huang.   

Abstract

Abnormalities of chromosome 22q have been well studied as a major molecular genetic event in meningiomas. Chromosome 14q loss has also been shown to be a common phenomenon. However, only a few studies have reported molecular genetic changes of this chromosome in meningioma. In this study, we examined 41 sporadic meningiomas of different histological subtypes and grades with 15 polymorphic microsatellite markers covering a wide region on chromosome 14q. Overall, 37% (15 of 41) of cases showed loss of heterozygosity for one or more allelic markers. Thirty percent (10 of 33) of benign tumors showed allelic losses, whereas 62.5% (5 of 8) of high-grade meningiomas showed loss of heterozygosity. There were altogether eight cases of partial deletions and seven cases of probable monosomy of 14q. Allelic losses of 14q were also commonly seen in recurrent tumors (3 of 3, 100%), parasagittal tumors (4 of 7, 57%), and tumors with transitional subtype (7 of 14, 50%). Among the tumors with allelic losses of 14q, all except one concurrently showed loss of heterozygosity for markers on 22q by our previous study. Of the eight cases with partial deletions, one showed losses on 14q11.1-31, two showed deletions on 14q24.3-31, three showed losses at 14q32.1-32.2, and the remaining two showed deletions at 14q24.3-32.2. We therefore defined two cluster regions of deletion on chromosome 14q: 14q24.3-31 and 14q32.1-32.2. Our studies suggested that more than one tumor suppressor gene(s) residing on distinct regions of chromosome 14q are important in the development and atypical or anaplastic changes in meningiomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9224744     DOI: 10.1016/s0046-8177(97)90149-0

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

1.  Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression.

Authors:  Xun Zhang; Roger Gejman; Ali Mahta; Ying Zhong; Kimberley A Rice; Yunli Zhou; Pornsuk Cheunsuchon; David N Louis; Anne Klibanski
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

Review 2.  Current status of human chromosome 14.

Authors:  D Kamnasaran; D W Cox
Journal:  J Med Genet       Date:  2002-02       Impact factor: 6.318

3.  The E6 oncoproteins of high-risk papillomaviruses bind to a novel putative GAP protein, E6TP1, and target it for degradation.

Authors:  Q Gao; S Srinivasan; S N Boyer; D E Wazer; V Band
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

4.  Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone.

Authors:  Angel Maillo; Alberto Orfao; Ana B Espinosa; José María Sayagués; Marta Merino; Pablo Sousa; Monica Lara; María Dolores Tabernero
Journal:  Neuro Oncol       Date:  2007-08-17       Impact factor: 12.300

5.  Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature.

Authors:  Jay Jagannathan; Rod J Oskouian; Hian Kwang Yeoh; Dwight Saulle; Aaron S Dumont
Journal:  Skull Base       Date:  2008-05

6.  MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.

Authors:  Aoife J Lowery; Nicola Miller; Amanda Devaney; Roisin E McNeill; Pamela A Davoren; Christophe Lemetre; Vladimir Benes; Sabine Schmidt; Jonathon Blake; Graham Ball; Michael J Kerin
Journal:  Breast Cancer Res       Date:  2009-05-11       Impact factor: 6.466

7.  High-resolution genome-wide allelotype analysis identifies loss of chromosome 14q as a recurrent genetic alteration in astrocytic tumours.

Authors:  J Hu; J C-S Pang; C Y-K Tong; B Lau; X-L Yin; W-S Poon; C-C Jiang; L-F Zhou; H-K Ng
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

8.  miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity.

Authors:  Keith O'Brien; Michelle C Lowry; Claire Corcoran; Vanesa G Martinez; Melissa Daly; Sweta Rani; William M Gallagher; Marek W Radomski; Roderick A F MacLeod; Lorraine O'Driscoll
Journal:  Oncotarget       Date:  2015-10-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.